Jefferies Financial Group’s Castle Biosciences CSTL Stock Holding History

Jefferies Financial Group’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.4M	Buy	+647,391	New	+$14.4M	0.1%	182

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Financial Group's CSTL Position: Q2 2026 in Review

Jefferies Financial Group opened a new position in Castle Biosciences (CSTL) in Q2 2026: 647,391 shares worth $15.4M. The stake represents 0.1% of the portfolio and ranks #182 among its holdings.

177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Jefferies Financial Group held 647,391 shares of Castle Biosciences worth $15.4M as of Q2 2026.
Castle Biosciences was a new Jefferies Financial Group position in Q2 2026.
Castle Biosciences made up 0.1% of Jefferies Financial Group's portfolio in Q2 2026, its #182 holding.
177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.